BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the Company") presented a new study today at the Personalized Cancer Vaccine Summit (formerly known as the mRNA Cancer ...
DPX Formulations Superior to Mixing with Commonly Used Adjuvants DPX Without Antigen Cargo Has Immune Stimulating Properties Unique Potential for DPX in New Fields of Use VANCOUVER ...
ACS Publications’ commitment to publishing high-quality content continues to attract impactful research that addresses the world’s most important challenges.